Crossmark

Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)

Crossref DOI link: https://doi.org/10.1016/j.arbres.2022.07.017

Published Print: 2022-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Lal, Amos

Garces, Juan Pablo Domecq

Bansal, Vikas

Tekin, Aysun

Zec, Simon

Khanna, Ashish K.

Warner, Matthew A.

Christie, Amy B.

Cartin-Ceba, Rodrigo

Banner-Goodspeed, Valerie M.

Armaignac, Donna Lee

Cheruku, Sreekanth R.

Raju, Umamaheswara

Tarabichi, Yasir

Denson, Joshua L.

Kumar, Vishakha

Walkey, Allan

Boman, Karen

Deo, Neha

Kashyap, Rahul

Gajic, Ognjen
Funding

Funding for this research was provided by:

NHLBI

Louisiana Clinical and Translational Science Center (U54 GM104940)

National Center for Research Resources

Gordon and Betty Moore Foundation

Janssen Research and Development LLC

National Center for Advancing Translational Sciences (UL1 TR002377)

American Diabetes Association

Society of Critical Care Medicine

Navicent Health Foundation

National Institutes of Health

DOD

Edwards Lifesciences Corp
License Information

Text and Data Mining valid from 2022-11-01

Accepted Manuscript valid from 2023-11-01
More Information

This article is maintained by: Elsevier

Article Title: Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS)

Journal Title: Archivos de Bronconeumología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arbres.2022.07.017

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.bjorl.2020.11.019

Content Type: article

Copyright: © 2022 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below